The drug has shown strong results in phase 3 clinical trials, which are the basis for the new application to the FDA.

Intra-Cellular submitted its application to the FDA for Caplyta’s approval in major depressive disorder, potentially opening ...

A University of Queensland-led team analyzed data for 204 countries and territories, to assess global access to adequate ...

Depression is a common mental disorder. Some 300 million people in the world have it, or an estimated 3.8% of the population, ...

Major depressive disorder (MDD), commonly referred to as depression, is a serious medical condition that affects a person's ...

Emotional and cognitive improvements in depression treatment often occur simultaneously, while behavioral changes, like ...

Bright light therapy has shown significant promise in improving remission and response rates among patients with nonseasonal ...

A new study by researchers from China and the UK explores the link between depression and menstrual pain (dysmenorrhea), a ...

Scientists found disrupted brain connectivity in youth depression, especially in networks tied to introspection and attention ...

Cybin, Inc. ( (CYBN) ) has released its Q2 earnings. Here is a breakdown of the information Cybin, Inc. presented to its investors.Don't Miss ...

In the fall and winter seasons, this is an everyday occurrence for those with Seasonal Affective Disorder (SAD), a form of ...

Researchers have found 70 per cent of Australians diagnosed with major depressive disorder are not receiving even the minimal treatment necessary.